Notes
1Further information on ECCO 13 and webcasted sessions are available via the Federation of European Cancer Societies website at URL: http://www.fecs.be/emc.asp.
2The use of trade names is for product identification purposes only and does not imply endorsement.
References
Miller K, Wang M, Gralow J, et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100) [abstract]. Eur J Cancer Suppl 2005 Oct; 3 (2): 77
Bianchi G, Loibl S, Zamagni C, et al. A phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer [abstract 276]. Eur J Cancer Suppl 2005 Oct; 3 (2): 78
Stein SH, Gomez HL, Chavez MA, et al. Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISHamplified advanced or metastatic breast cancer [abstract 277]. Eur J Cancer Suppl 2005 Oct; 3 (2): 78
Storniolo AM, Burris III HA, Pegram MD, et al. Phase I study of lapatinib (GW572016) in combination with trastuzumab in advanced ErbB2-positive breast cancer [abstract 278]. Eur J Cancer Suppl 2005 Oct; 3 (2): 78
Gluz O, Ting E, Mohrmann S, et al. Basal-like subtype of breast carcinoma predicts poor clinical outcome in patients with high-risk breast cancer treated with high-dose or dose-dense chemotherapy: results of multivariate analysis from the WSG-AM-01 phase III trial [abstract 279]. Eur J Cancer Suppl 2005 Oct; 3 (2): 79
Dodwell D. Time to response: a comparison of fulvestrant with anastrozole [abstract 280]. Eur J Cancer Suppl 2005 Oct; 3 (2): 79
Untch M. Herceptin after adjuvant chemotherapy significantly improves diseasefree survival in HER2-positive early breast cancer: HERA trial interim analysis [abstract PS4]. Eur J Cancer Suppl 2005 Oct; 3 (4): 4
Romond EH, Perez EA, Bryant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER2-positive operable breast cancer: combined analysis of NSABP B-31 and NCCTG N9831 [abstract 263]. Eur J Cancer Suppl 2005 Oct; 3 (2): 73
Perez E, Suman VJ, Davidson N, et al. Concurrent trastuzumab and paclitaxel treatment improves disease-free survival in resected HER2-positive breast cancer: NCCTG N9831 interim analysis [abstract 264]. Eur J Cancer Suppl 2005 Oct; 3 (2): 74
Slamon D, Eiermann W, Robert N, et al. BCIRG 006: superior cardiac safety of adjuvant docetaxel, carboplatin and trastuzumab compared to doxorubicin and cyclophosphamide followed by TH in patients with early stage breast cancer and altered HER2 gene [abstract 265]. Eur J Cancer Suppl 2005 Oct; 3 (2): 74
Ingle J, Goss P, Dongsheng T. NCIC CTG MA17: increasing benefit of letrozole with longer duration of treatment as measured by the hazard ratio of disease recurrence over time [abstract 266]. Eur J Cancer Suppl 2005 Oct; 3 (2): 74
Goss P, Ingle J, Dongsheng T, et al. 17 Collaborative Trialists. Oral NCIC CTG MA17: disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor [abstract 267]. Eur J Cancer Suppl 2005 Oct; 3 (2): 74–5
Duffy S, ATAC Trialists’ Group. Gynaecological adverse events and hysterectomies in the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial [abstract 268]. Eur J Cancer Suppl 2005 Oct; 3 (2): 75
Women may avoid the life-threatening side effects associated with some hormonal early breast cancer therapies by initiating treatment with arimidex?. Press release 2005 Nov 1 [online]. Available from URL: http://www.astrazenecapressoffice.com/index.asp?.did=172&aid=8896 [Accessed 2005 Nov 28]
Herrstedt J, Plaza J, Schmalfeldt B, et al. Paclitaxel-carboplatin-gemcitabine versus paclitaxel-carboplatin as first line treatment in women with ovarian cancer: a randomized phase III GCIG Intergroup study (AGO-OVAR9, GINECO-TCG, NSGO-OC-0102) [abstract 902]. Eur J Cancer Suppl 2005 Oct; 3 (2): 259
Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of single agent pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status [abstract 903]. Eur J Cancer Suppl 2005 Oct; 3 (2): 259–60
Veerasarn V, Lorvidhaya V, Suntornpong N, et al. A randomized phase III trial of concurrent chemoradiation in locally advanced cervical cancer: preliminary results [abstract 905]. Eur J Cancer Suppl 2005 Oct; 3 (2): 260
Oza AM, Elit L, Biagi J, et al. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or recurrent endometrial cancer — NCIC CTG IND 160 [abstract 907]. Eur J Cancer Suppl 2005 Oct; 3 (2): 261
Glimelius B, Sørbye H, Balteskard L, et al. A randomised phase III multicenter trial comparing irinotecan in combination with either the Nordic bolus 5FU and folinic acid schedule or the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer [abstract 597]. Eur J Cancer Suppl 2005 Oct; 3 (2): 167
Fischer Von Weikersthal L, Schalhorn A, Quietzsch D, et al. Randomised comparison of 5-FU/folinic acid plus irinotecan and irinotecan plus oxaliplatin in firstline therapy of metastatic colorectal cancer: the fire-trial [abstract 598]. Eur J Cancer Suppl 2005 Oct; 3 (2): 167
Falcone A, Brunetti IM, Benedetti G, et al. Improved activity with irinotecan, oxaliplatin and infusional 5-FU/LV compared with FOLFIRI in metastatic colorectal cancer: results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest [abstract 599]. Eur J Cancer Suppl 2005 Oct; 3 (2): 167–8
Punt C, Douma J, Honkoop A, et al. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer, an interim safety analysis: a Dutch Colorectal Cancer Group phase III study [abstract 600]. Eur J Cancer Suppl 2005 Oct; 3 (2): 168
Arkenau H, Kubicka S, Greil R, et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin versus capecitabine plus oxaliplatin as first line treatment of metastatic colorectal carcinoma: results of the safety and efficacy analysis [abstract 601]. Eur J Cancer Suppl 2005 Oct; 3 (2): 168
Georgoulias V, Berry S, Di Bartolomeo M, et al. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC — First BEATrial [abstract 602]. Eur J Cancer Suppl 2005 Oct; 3 (2): 168–9
Ault K, GARDASIL TM Phase III Steering Committee. Prophylactic use of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine reduces cervical intraepithelial neoplasia 2/3 and adeocarcinoma in situ risk [abstract PS10]. Eur J Cancer Suppl 2005 Oct; 3 (4): 11
Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer [abstract PS11]. Eur J Cancer Suppl 2005 Oct; 3 (4): 12
O’Byrne KJ, Bonomi P, Paz-Ares L, et al. Paclitaxel poliglumex vs. docetaxel for the second-line treatment of non-small cell lung cancer: the STELLAR 2 phase III study [abstract PS13]. Eur J Cancer Suppl 2005 Oct; 3 (4): 14
Van Meerbeeck J. A randomized trial of radical surgery versus thoracic radiotherapy in patients with stage IIIA-N2 non-small cell lung cancer after response to induction chemotherapy (EORTC 08941) [abstract 1120]. Eur J Cancer Suppl 2005 Oct; 3 (2): 323
Smith I, Groen HJM, Van Meerbeeck J, et al. The impact of giving neo-adjuvant chemotherapy for patients with non-small cell lung cancer: data from the MRC LU22/NVALT/EORTC 08012 randomised clinical trial [abstract 1121]. Eur J Cancer Suppl 2005 Oct; 3 (2): 323–4
O’Brien M, Oldham F. Paclitaxel poliglumex vs. gemcitabine or vinorelbine for the treatment of performance status 2 patients with chemotherapy-naive advanced non-small cell lung cancer: the STELLAR 4 phase III study [abstract 1122]. Eur J Cancer Suppl 2005 Oct; 3 (2): 324
Crawford J, Swanson P, Prager D, et al. Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for the first line advanced non-small cell lung cancer: a primary analysis [abstract 1123]. Eur J Cancer Suppl 2005 Oct; 3 (2): 324
Ranson M, Bodkin D, Govindan R, et al. Results of a randomized, double-blind phase II trial of ZD6474 versus gefitinib in patients with NSCLC [abstract 1124]. Eur J Cancer Suppl 2005 Oct; 3 (2): 324–5
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bothwell, A. 13th European Cancer Conference — ECCO 13. Int J Pharm Med 19, 333–341 (2005). https://doi.org/10.2165/00124363-200519050-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00124363-200519050-00011